Caldera-Synlogic Merger and $278 Million Raise Bolster Qyuns-Linked IBD Program
I'm LongbridgeAI, I can summarize articles.Caldera Therapeutics is merging with Synlogic in an all-stock deal to form a Nasdaq-listed holding company, CALD. Concurrently, Caldera raised $278 million via private placement for Phase II IBD trials of QX030N/CLD-423. This development strengthens Qyuns Therapeutics (HK:2509), which holds an equity stake and licenses the drug globally, enhancing its strategic position despite dilution.
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) just unveiled an announcement.
Caldera Therapeutics, Qyuns Therapeutics’ partner for the investigational IBD drug QX030N/CLD-423, has agreed to merge with Synlogic in an all-stock deal that will create a new holding company listed on the Nasdaq Capital Market under the ticker CALD. The combined entity will be led by Caldera’s current chief executive and governed by its existing board, with pre-merger Caldera shareholders expected to hold the majority stake and Synlogic investors retaining a small minority interest subject to net cash adjustments.
To support the merger and subsequent development plans, Caldera has arranged a concurrent private placement expected to raise about $278 million from a roster of prominent healthcare-focused institutional investors and mutual funds. The proceeds are earmarked primarily for Phase II clinical trials of QX030N/CLD-423 in ulcerative colitis and Crohn’s disease, as well as potential expansion into other immune-mediated conditions, enhancing the asset’s value and indirectly strengthening Qyuns Therapeutics’ strategic position as a licensor and shareholder.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a China-based biopharmaceutical company focused on developing innovative therapies for inflammatory and immune-mediated diseases. Its portfolio includes investigational biologics such as QX030N/CLD-423, a bispecific antibody targeting TL1A and IL-23p19 pathways for inflammatory bowel disease, positioning the firm within the advanced immunology and IBD treatment segment.
The company collaborates with Caldera Therapeutics through a global out-licensing deal for QX030N/CLD-423 and holds an equity stake that was diluted from 24.88% to about 11.48% following Caldera’s Series A-1 financing. This partnership aligns Qyuns with international biotech capital markets and clinical development infrastructure, expanding its global footprint despite a reduced ownership share.
Average Trading Volume: 197,485
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$3.68B
For a thorough assessment of 2509 stock, go to TipRanks’ Stock Analysis page.